mrna

Featured image of the post Replicate Bioscience unveils promising clinical progress on self-amplifying RNA at ASGCT annual meeting.

Replicate Bioscience unveils promising clinical progress on self-amplifying RNA at ASGCT annual meeting

Posted on by

SOPHIA ANTIPOLIS, France – May 13, 2024 │ KnowMade actively follows therapeutic mRNA news for its Therapeutic mRNA patent monitor service! What’s new today? REPLICATE BIOSCIENCE develops novel self-amplifying RNA (or self-replicating or srRNA) technology for use across a range of application (i.e., infectious disease, oncology, or autoimmune disease). This clinical-stage company was already identified[…]

Featured image of Q12024 mRNA monitor Press release.

Q1 2024 IP Activity Reveals Growth and Litigation in Key mRNA Market

Posted on by

SOPHIA ANTIPOLIS, France – April 18, 2024 │ The quarterly report for the Q1 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. What’s new this quarter? Q1 2024 IP Activity overview The IP activity during Q1 2024 follow 2023’s[…]

Featured image of our press release upon Q4 2023 patent monitor.

Q4 2023 Therapeutic mRNA patent monitor report: IP dynamic overview

Posted on by

SOPHIA ANTIPOLIS, France – January 22, 2024 │ The quarterly report for the Q4 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. What’s new this quarter? Q4 2023 IP Activity overview The IP activity during Q4 2023 is consistent[…]

Featured image of the article A look back at mRNA patenting activity for 2023.

A look back at mRNA patenting activity for 2023

Posted on by

SOPHIA ANTIPOLIS, France – January 16, 2024 │ The last quarterly report for the 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. As we leave behind another year, we look back on the mRNA therapeutic patenting activity! Q4 2023[…]